Provochonline Solution Logo

Diagnose Exercise-Induced Bronchoconstriction and Asthma with Confidence

Introducing Aridol® (mannitol challenge test) to assess patients experiencing respiratory symptoms and suspected of having asthma or exercise-induced bronchoconstriction (EIB). It provides convenience in an all-in-one standardized kit to test adults and children 6 years of age and older. Aridol is a quick and easy alternative to exercise testing.

Aridol Canada photo

Assess Airway Hyperreactivity:

When asthma is suspected

When symptoms occur with physical activity

To rule out conditions with similar symptoms to asthma

To determine the effectiveness of inhaled corticosteroid therapy and response to asthma treatments

To determine the level of airway inflammation

Two women, doctor and patient, looking at a clipboard

Product Information

Product Monograph

Aridol Product Information

Inhalation Guide

Aridol Product Information
Information for Patients
Aridol Product Information

Medication Withholding

Aridol Medication Withholding

Aridol Bronchial Challenge Test

This video provides an introduction to the Aridol Bronchial Challenge Test. The video was developed for US healthcare practitioners and is provided here as a reference only. For additional information, questions or to schedule comprehensive training, including hands-on mock test training, please contact Methapharm.


Mannitol, the active ingredient in Aridol, acts as a bronchoconstrictor and may cause severe bronchospasm. Bronchial challenge testing with Aridol is for diagnostic purposes only. Bronchial challenge testing with Aridol should only be conducted by trained professionals under the supervision of a physician familiar with all aspects of the bronchial challenge test and the management of acute bronchospasm. Medications (such as short acting inhaled beta agonist) and equipment to treat severe bronchospasm must be present in the testing area. If severe bronchospasm occurs it should be treated immediately by administration of a short acting inhaled beta agonist. Because of the potential for severe bronchoconstriction, the bronchial challenge testing with Aridol should not be performed in any patient with clinically apparent asthma or very low baseline pulmonary function tests (e.g., FEV1<1-1.5 liters or <70% of the predicted values).